FINNENCE ▪ THE WIRE FILE
THE WIRE · № 62053
News■ Unclear/unknown
Clinical Trial Supplies Market worth $8.95 billion by 2031
KINDNews
DIRECTION■ Unclear/unknown
SOURCES1
ENTITIES1
STORY SIZESTANDALONE
FIRST SEEN2026-10-02 14:30 UTC
LAST UPDATE2026-10-02 14:30 UTC
STATEactive
01 THE MACHINE READ
WHY IT MATTERS.
A paid market-research forecast for clinical trial supplies implies growth in trial activity but names no listed beneficiary.
Vendor market-sizing report, limited tradeable content
CATALYST TO WATCH
Actual trial-spend data from CROs
MAIN RISK
Forecast is vendor-sponsored and unverifiable
FULL DISPATCH
DELRAY BEACH, Fla., Oct. 2, 2026 /PRNewswire/ -- According to MarketsandMarkets™, the Clinical Trial Supplies Market is projected to reach USD 8.95 billion by 2031 from USD 5.60 billion in 2026, at a CAGR of 8.9% during the forecast period. Browse 420 market data Tables and 50 Figures...
02 THE STORY SO FAR
THE RECORD, IN ORDER.
STANDALONE ITEM — NOT YET FOLDED INTO A DEVELOPING STORY.
03 WHO'S INVOLVED
ENTITIES ON FILE.
AFFECTEDHealthcare
04 RECEIPTS
THE SOURCE RECORD.
1 SOURCES CONFIRMED05 PROPAGATION
WHAT THIS TOUCHES.
→CORRELATIONshares Healthcare
Teva, Samsung Bioepis deepen bonds in pact for up to 6 new biosimilars2026-10-02 14:00 UTC
Teva, Samsung Bioepis deepen bonds in pact for up to 6 new biosimilars2026-10-02 14:00 UTC
→CORRELATIONshares Healthcare
BioMarin Announces Five-Year Phase 3 Data for POMBILITI® (cipaglucosidase alfa-atga) + OPFOLDA® (miglustat) at World Muscle Society Annual Congress2026-10-02 15:00 UTC
BioMarin Announces Five-Year Phase 3 Data for POMBILITI® (cipaglucosidase alfa-atga) + OPFOLDA® (miglustat) at World Muscle Society Annual Congress2026-10-02 15:00 UTC
←CORRELATIONshares Healthcare
Angel Aligner actualiza Torque Ridges a "Pressure Points" en Europa2026-10-02 08:46 UTC
Angel Aligner actualiza Torque Ridges a "Pressure Points" en Europa2026-10-02 08:46 UTC
←CORRELATIONshares Healthcare
New Research on Postpartum Depression vs. Depression: What Brain Imaging Reveals2026-10-02 09:00 UTC
New Research on Postpartum Depression vs. Depression: What Brain Imaging Reveals2026-10-02 09:00 UTC
←CORRELATIONshares Healthcare
Ascletis' ASC36_35FDC Demonstrated Potential for Once-Monthly to Once-Quarterly Dosing and Robust Weight-Loss in Preclinical Studies Presented at EASD 20262026-10-02 09:00 UTC
Ascletis' ASC36_35FDC Demonstrated Potential for Once-Monthly to Once-Quarterly Dosing and Robust Weight-Loss in Preclinical Studies Presented at EASD 20262026-10-02 09:00 UTC
←CORRELATIONshares Healthcare
19,3 % Gewichtsverlust in Woche 48: Daten der Phase-III-Studie zu Olatorepatid, Hansohs dualem, biased GLP-1/GIP-Agonisten, auf der EASD-Tagung vorgestellt2026-10-02 09:41 UTC
19,3 % Gewichtsverlust in Woche 48: Daten der Phase-III-Studie zu Olatorepatid, Hansohs dualem, biased GLP-1/GIP-Agonisten, auf der EASD-Tagung vorgestellt2026-10-02 09:41 UTC
KEEP READING THE MACHINE
Summaries are generated and may contain errors — every claim links its sources.